Scrip 100: Lawmakers seek R&D enterprise overhaul for faster cures
This article was originally published in Scrip
With the rest of the world seeking to take the competitive lead away from the US in biomedical innovation, Representatives Fred Upton (Republican-Michigan) and Diana DeGette (Democrat-Colorado) in May declared it was time to go big – launching a new initiative aimed at finding ways to accelerate the nation's discovery, development and delivery processes for new medicines.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.